Insulin Resistance Is Associated With Circulating Fibrinogen Levels in Nondiabetic Patients Receiving Peritoneal Dialysis

Journal of Renal Nutrition

Volumn 17, Issue 2, 2007, Pages 132-137

  Martins, Cristina ^a,b,d   Mazza do Nascimento, Marcelo ^a,c   Pecoits Filho, Roberto ^a,c,d   Leinig, Cyntia ^a,d   Gonçalves, Luiz Felipe ^b   Fuerbringer, Roseana ^a   Stenvinkel, Peter ^c   Lindholm, Bengt ^c   Riella, Miguel Carlos ^a,d  

^a ProRenal Foundation   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c KAROLINSKA INSTITUTE   (Sweden)

^d PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHYSIOLOGY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; FIBRINOGEN; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY;

EID: 33847166251     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2006.07.004     Document Type: Article

References (31)

1. Shinohara K., Shoji T., Emoto M., et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13 7 (2002) 1894-1900
2. Fliser D., Pacini G., Engelleiter R., et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53 5 (1998) 1343-1347
3. Delarue J., Maingourd C., Couet C., et al. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Perit Dial Int 18 5 (1998) 505-511
4. Kobayashi K. Adipokines: therapeutic targets for metabolic syndrome. Curr Drug Targets 6 4 (2005) 525-529
5. Vendrell J., Broch M., Vilarrasa N., et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12 6 (2004) 962-971
6. Gale S.M., Castracane V.D., and Mantzoros C.S. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. J Nutr 134 2 (2004) 295-298
7. Furuya R., Odamaki M., Kumagai H., et al. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 21 2 (2006) 494-498
8. Prinsen B.H., Rabelink T.J., Beutler J.J., et al. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int 64 4 (2003) 1495-1504
9. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894 (2000) 1-253 i-xii
10. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 7 (1985) 412-419
11. Rosenson R.S., Tangney C.C., and Schaefer E.J. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 155 2 (2001) 463-436
12. Grey A.B., Stapleton J.P., Evans M.C., et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80 11 (1995) 3191-3195
13. Hauser E., Seidl R., Freilinger M., et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 18 2 (1996) 105-109
14. Gralnick H.R., and Henderson E. Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer 27 6 (1971) 1313-1320
15. Becker B., Kronenberg F., Kielstein J.T., et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16 4 (2005) 1091-1098
16. Fernstrom A., Hylander B., Moritz A., et al. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 18 2 (1998) 166-171
17. Nascimento M.M., Pecoits-Filho R., Qureski A.R., et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transpl 19 11 (2004) 2803-2809
18. Barazzoni R., Kiwanuka E., Zanetti M., et al. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes 52 (2003) 1851-1856
19. Goldwasser P., Feldman J.G., Emiru M., et al. Effect of dialysis modality on plasma fibrinogen concentration: a meta-analysis. Am J Kidney Dis 44 (2004) 941-949
20. DeFronzo R.A., Smith D., and Alvestrand A. Insulin action in uremia. Kidney Int Suppl 16 (1983) S102-S114
21. Hager S.R. Insulin resistance of uremia. Am J Kidney Dis 14 4 (1989) 272-276
22. Kobayashi S., Maejima S., Ikeda T., et al. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 15 1 (2000) 65-70
23. Mak R.H. Insulin resistance in uremia: effect of dialysis modality. Pediatr Res 40 2 (1996) 304-308
24. Lin S.H., Lin Y.F., Kuo S.W., et al. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis 42 4 (2003) 774-780
25. Delarue J., and Maingourd C. Acute metabolic effects of dialysis fluids during CAPD. Am J Kidney Dis 37 1 Suppl 2 (2001) S103-S107
26. Festa A., Hanley A.J., Tracy R.P., et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108 15 (2003) 1822-1830
27. Senn J.J., Klover P.J., Nowak I.A., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278 16 (2003) 13740-13746
28. Lang C.H., Dobrescu C., and Bagby G.J. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130 1 (1992) 43-52
29. Axelsson J., Heimburger O., Lindholm B., et al. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 15 1 (2005) 131-136
30. Pereira B.J., Shapiro L., King A.J., et al. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45 3 (1994) 890-896
31. Pecoits-Filho R., Lindholm B., and Stenvinkel P. End-stage renal disease: a state of chronic inflammation and hyperleptinemia. Eur J Clin Invest 33 6 (2003) 527-528